Comprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com
The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape markets, especially in the realm of respiratory diagnostics, where a…
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) has finalized its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for an estimated total equity value of about $4.3 billion. This strategic move enhances Gilead’s liver disease portfolio by incorporating CymaBay’s leading investigational product, seladelpar,…
GenSight Biologics Releases Comprehensive Financial Summary for Fiscal Year 2023
GenSight Biologics, a biopharmaceutical company listed on Euronext under the ticker symbol SIGHT and ISIN FR0013183985, eligible for PEA-PME, has disclosed its consolidated financial performance for the full year 2023. This report, approved by the Board of Directors on March…
2024 Biopharma-Site Network Pulse Report: Insights from IQVIA, ICON, Parexel, Fortrea, PPD/Thermo Fisher, and Syneos Health – Research And Markets.com
The “2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report” has been added to ResearchAndMarkets.com’s offering. The landscape of biopharmaceutical clinical development is in a constant state of flux and progression. While major global Contract Research Organizations (CROs) cater to a significant portion…
Otsuka Pharma’s Indonesian Subsidiaries Earn Exemplar Award from EWTB for Tuberculosis Eradication Efforts
Otsuka Pharmaceutical proudly announces that its subsidiaries in Indonesia, PT Otsuka Indonesia (PTOI) and PT Amerta Indah Otsuka (PTAIO), have been honored with the prestigious 2024 Ending Workplace Tuberculosis (EWTB) Exemplar Award. This esteemed recognition, coinciding with World TB Day…
CHMP Recommends Novartis Fabhalta® for Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion, recommending the authorization…
FDA Fully Approves ELAHERE® for Specific Ovarian Cancer Patients
AbbVie (NYSE: ABBV) has announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for treating folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal adult cancer patients who…
Ono Collaborates with University of Oxford for Extensive Drug Discovery Partnership
Today, it was announced that Ono has initiated a comprehensive collaboration for drug discovery with the University of Oxford in Oxfordshire, UK. This collaboration aims to explore and validate drug discovery seeds, as well as to obtain screening compounds to…
Bio-Techne Attains European IVDR Certification for Diagnostic Test Monitoring Chronic Myeloid Leukemia
Bio-Techne Corporation (NASDAQ: TECH) has announced today that its Molecular Diagnostics Division, Asuragen, has successfully obtained Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. This certification marks a…
WuXi Biologics Named to CDP ‘A List’ for Water Security
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its recognition for exemplary corporate transparency and commitment to water security by the esteemed environmental non-profit CDP, securing its position on the prestigious annual…
UCB’s BIMZELX[®]▼ (bimekizumab) Gains Favorable CHMP Opinion for treatment Moderate to Severe Hidradenitis Suppurativa in Adults
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion, recommending the granting of marketing authorization for BIMZELX® (bimekizumab) within…
Bayer and Trinity Agtech Collaborate to Advance Regenerative Agriculture Practices
In a strategic move towards advancing regenerative agriculture, Bayer has announced a partnership with Trinity Agtech, a UK-based company. This collaboration aims to leverage Trinity Agtech’s platform, Sandy, as a cornerstone in Bayer’s Carbon Initiative across the EMEA region, facilitating…